Medivation Earnings: Everything You Must Know Now

Medivation, Inc. (NASDAQ:MDVN) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company.

Medivation, Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased to $-0.07 in the quarter versus EPS of $-0.08 in the year-earlier quarter.

Revenue: Rose 63.48% to $70.15 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Medivation, Inc. reported adjusted EPS loss of $0.07 per share. By that measure, the company beat the mean analyst estimate of $-0.21. It beat the average revenue estimate of $59.35 million.

Quoting Management: “The European Union’s recent decision to grant XTANDI marketing authorization marks an important milestone as access to XTANDI begins to expand beyond the United States,” said David Hung, M.D., president and chief executive officer of Medivation, Inc. “Medivation and Astellas also achieved significant clinical milestones for XTANDI during the quarter by completing enrollment in the Phase 2 TERRAIN trial evaluating enzalutamide head-to-head versus bicalutamide and initiating a Phase 2 trial in androgen receptor positive, triple-negative breast cancer, where there is a significant unmet need. We and Astellas look forward to the results of the interim analysis for PREVAIL, our Phase 3 trial in men with advanced prostate cancer who have not yet received chemotherapy, which will occur in 2013.”

Key Stats (on next page)…

Revenue increased 52% from $46.15 million in the previous quarter. EPS increased to $-0.07 in the quarter versus EPS of $-0.36 in the previous quarter.

Looking Forward: Analysts have a more positive outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has risen from a loss of $0.22 to a loss $0.20. For the current year, the average estimate has moved up from a loss of $1.01 to a loss of $0.97 over the last ninety days.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]